Hallucination development with montelukast in a child with asthma: Case presentation

Iranian Journal of Allergy, Asthma and Immunology

Volumn 12, Issue 4, 2013, Pages 397-399

  Kocyigit, Aysen ^a   Oksuz, Banu Gulcan ^a   Yarar, Fulya ^b   Uzun, Funda ^c   Igde, Mahir ^a   Islek, Ismail ^d  

^a Samsun Education and Research Hospital   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^c Samsun Maternity and Child Health Hospital   (Turkey)

^d Umraniye Education and Research Hospital   (Turkey)

Author keywords

Adverse reactions; Asthma; Children; Hallucination; Montelukast

Indexed keywords

BUDESONIDE; FORMOTEROL; METHYLPHENIDATE; MONTELUKAST; PREDNISOLONE; SALBUTAMOL; THIORIDAZINE;

ABNORMAL RESPIRATORY SOUND; ADOLESCENT; ANXIETY DISORDER; ARTICLE; ASTHMA; CASE REPORT; COUGHING; DRUG WITHDRAWAL; DYSPNEA; FOLLOW UP; HUMAN; HYPERACTIVITY; INSOMNIA; MALE; RESPIRATORY DISTRESS; TREATMENT WITHDRAWAL; VISUAL HALLUCINATION;

ACETATES; ADOLESCENT; ADULT; ASTHMA; HALLUCINATIONS; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; QUINOLINES;

EID: 84888242938     PISSN: 17351502     EISSN: 17355249     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy. N Engl J Med 2011; 364(18):1695-707.
2. Igde M, Anlar FY. The efficacy of montelukast monotherapy in moderate persistent asthmatic children. Iran J Allergy Asthma Immunol 2009; 8(3):169-70.
3. Barnes PJ, Drazen JM, Rennard SI, Thompson NC editors. Pathophysiology of asthma. In Asthma and COPD: Basic Mechanisms and Clinical Management. 2nd edition, 2009; 33:401-19.
4. Mandeep W, Rakesh L, Kabra SK. Montelukast in Pediatric Asthma Management. Indian J Pediatr 2006; 73(4):275-82. (Pubitemid 44326182)
5. Visitsunthorn N, Chirdjirapong V, Santadilog S, Pajarn P, Jirapongsananuruk O, Komoltri C, et al. The effect of montelukast on bronchial hyperreactivity and lung function in asthmatic children aged 6-13 years. Asian Pac J Allergy Immunol 2011; 29(2):127-33.
6. Bond WS. Recognition and treatment of attention deficit disorder. Clin Pharm 1987; 6(8):617-24. (Pubitemid 17137216)
7. Wallerstedt SM, Brunlöf G, Sundström A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009; 18(9):858-64.
8. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124(4):699-706.
9. Anandan N, Ibitoye F. Montelukast and worsening of hallucinationsin paranoid schizophrenia. The Psychiatrist. 2008; 32:276. (Pubitemid 351943669)
10. Boyce JA. Mast cells: beyond IgE. J Allergy Clin Immunol 2003; 111(1):24-32. (Pubitemid 36143285)
11. Postolache TT, Komarow H, Tonelli LH. Allergy: A risk factor for suicide? Curr Treat Options Neurol 2008; 10(5):363-76.